Effective communication, cultural competence, and patient advocacy are keys to overcoming language barriers in eye care, as ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

The positive CHMP opinion is supported by data from the pivotal LINKER-MM1 trial, which evaluated linvoseltamab in adults with R/R MM. Earlier this month, the FDA accepted for review the Biologics ...

From uncertainty to hope for the future, they offer advice on getting through some of the toughest years of their lives ...

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible ...

Although the treatment of myeloma has changed dramatically after the readout of many recent trials, key unanswered questions ...

He’d been fighting multiple myeloma for nearly five years ... At the end of that 2022 interview with Bauer, joy lit up his eyes like sunshine as he talked about his life’s work.

Multiple myeloma is a type of blood cancer that forms in plasma cells, white blood cells that produce infection-fighting antibodies. Multiple myeloma is not hereditary, meaning it is not passed ...

Saad Usmani, Chief of MSK's Myeloma Service, says there are far more treatment options for multiple myeloma today compared with just 20 years ago. Note: This story was originally published in 2022 and ...

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.